No Picture
Trading Ideas

Regeneron’s newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company’s future sales growth as its best-selling eye drug Eylea faces more competition. Regeneron is bracing for a hit to Eylea’s sales by focusing on expanding Dupixent’s label to reach more patients and venturing into the hot new field of immuno-oncology with a potential regulatory approval later this year. Just two days ago, Regeneron and partner Sanofi SA slashed the price on Praluent by more …read more […]

No Picture
Business News

Rolls-Royce says working quickly to fix Trent 1000 problems

LONDON (Reuters) – Britain’s Rolls-Royce is working quickly to repair problems with some of its Trent 1000 engines that have left planes grounded, it said on Thursday, adding it remained confident the cost would not cause it to miss financial forecasts. Rolls-Royce was questioned at its annual shareholder meeting about problems with the Trent 1000 package C, the engine used to power some Boeing Dreamliner 787 planes, in what is a new headache for a company in turnar

…read more […]